Head-to-head evidence
iPS-NSC cells vs RNDP-001
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopaminergic neuron replacement · full Parkinson's Disease pipeline
iPS-NSC cells
Developed by Allife Medical Science and Technology
NCT03815071 · Phase 1 · status unknown
This is a small, single-arm, unblinded study of 10 participants with no control group, designed to check safety rather than test efficacy against a comparator, and results have not yet been posted.
RNDP-001
Developed by Kenai Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: September 2027 · NCT07106021 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: iPS-NSC cells's landscape · RNDP-001's landscape